Association of microRNA-146a with autoimmune diseases

Inflammation

Volumn 35, Issue 4, 2012, Pages 1525-1529

  Xu, Wang Dong ^a   Lu, Man Man ^a   Pan, Hai Feng ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Autoimmune diseases; Autoimmunity; MiR 146a

Indexed keywords

MESSENGER RNA; MICRORNA 146A; NUCLEOTIDE; UNTRANSLATED RNA;

ARTICLE; AUTOIMMUNE DISEASE; CHROMOSOME 5; DISEASE ASSOCIATION; EXON; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATION; NONHUMAN; RHEUMATOID ARTHRITIS; RNA DEGRADATION; RNA TRANSLATION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICRORNAS; SJOGREN'S SYNDROME;

EID: 84866742491     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9467-0     Document Type: Article

References (44)

1. Luo, X., L.M. Tsai, N. Shen, and D. Yu. 2010. Evidence for microRNA-mediated regulation in rheumatic diseases. Annals of the Rheumatic Diseases 69(Suppl I): i30-i36.
2. Taganov, K.D., M.P. Boldin, K.J. Chang, and D. Baltimore. 2006. NF-?B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences of the United States of America 103: 12481-12486.
3. Vyse, T.J., and B.L. Kotzin. 1996. Genetic basis of systemic lupus erythematosus. Current Opinion in Immunology 8: 843-851.
4. Tang, Y., X. Luo, H. Cui, X. Ni, M. Yuan, Y. Guo, X. Huang, H. Zhou, N. de Vries, P.P. Tak, S. Chen, and N. Shen. 2009. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis & Rheumatism 60: 1065-1075.
5. Vollmer, J., S. Tluk, C. Schmitz, S. Hamm, M. Jurk, A. Forsbach, S. Akira, K.M. Kelly, W.H. Reeves, S. Bauer, and A.M. Krieg. 2005. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. The Journal of Experimental Medicine 202: 1575-1585.
6. Means, T.K., E. Latz, F. Hayashi, et al. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. Journal of Clinical Investigation 115: 407-417.
7. Barrat, F.J., T. Meeker, J. Gregorio, J.H. Chan, S. Uematsu, S. Akira, B. Chang, O. Duramad, and R.L. Coffman. 2005. Nucleic acids of mammalian origin can act as endogenous ligands for Tolllike receptors and may promote systemic lupus erythematosus. The Journal of Experimental Medicine 202: 1131-1139.
8. Uematsu, S., S. Sato, M. Yamamoto, T. Hirotani, H. Kato, F. Takeshita, M. Matsuda, C. Coban, K.J. Ishii, T. Kawai, O. Takeuchi, and S. Akira. 2005. Interleukin-1 receptor-Associated kinase-1 plays an essential role for Toll-like receptor (TLR)7-And TLR9-mediated interferon-{alpha} induction. The Journal of Experimental Medicine 201: 915-923.
9. Kawai, T., S. Sato, K.J. Ishii, C. Coban, H. Hemmi, M. Yamamoto, K. Terai, M. Matsuda, J. Inoue, S. Uematsu, O. Takeuchi, and S. Akira. 2004. Interferon-A induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nature Immunology 5: 1061-1068.
10. Schoenemeyer, A., B.J. Barnes, M.E. Mancl, E. Latz, N. Goutagny, P.M. Pitha, K.A. Fitzgerald, and D.T. Golenbock. 2005. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. Journal of Biological Chemistry 280: 17005-17012.
11. Li, Q.J., J. Chau, P.J. Ebert, G. Sylvester, H. Min, G. Liu, R. Braich, M. Manoharan, J. Soutschek, P. Skare, L.O. Klein, M.M. Davis, and C.Z. Chen. 2007. miR-181a is an intrinsic modulator of t cell sensitivity and selection. Cell 129: 147-161.
12. Platanias, L.C. 2005. Mechanisms of type I and type II interferon mediated signalling. Nature Reviews Immunology 5: 375-386.
13. Dai, R., Y. Zhang, D. Khan, B. Heid, D. Caudell, O. Crasta, and S.A. Ahmed. 2010. Identification of a common lupus diseaseassociated microRNA expression pattern in three different murine models of lupus. PLoS One 5: e14302.
14. Pan, Q., X. Luo, and N. Chegini. 2010. microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. Molecular Human Reproduction 16: 215-227.
15. Lu, J., B.C.Kwan, F.M. Lai, L.S. Tam, E.K. Li, K.M. Chow, G.Wang, P.K. Li, and C.C. Szeto. 2012. Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. Nephrology (Carlton, Vic.). doi:10.1111/j.1440-1797.2012.01573.x.
16. Pauley, K.M., S. Cha, and E.K. Chan. 2009. MicroRNA in autoimmunity and autoimmune diseases. Journal of Autoimmunity 32: 189-194.
17. Lu, L.F., M.P. Boldin, A. Chaudhry, L.L. Lin, K.D. Taganov, T. Hanada, A. Yoshimura, D. Baltimore, and A.Y. Rudensky. 2010. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142: 914-929.
18. Luo, X., W. Yang, D.Q. Ye, H. Cui, Y. Zhang, N. Hirankarn, X. Qian, Y. Tang, Y.L. Lau, N. de Vries, P.P. Tak, B.P. Tsao, and N. Shen. 2011. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 7: e1002128.
19. Zhang, J., B. Yang, B. Ying, D. Li, Y. Shi, X. Song, B. Cai, Z. Huang, Y. Wu, and L. Wang. 2011. Association of pre-microRNAs genetic variants with susceptibility in systemic lupus erythematosus. Molecular Biology Reports 38: 1463-1468.
20. Löfgren, S.E., Frostegård, J., Truedsson, L., Pons-Estel, B.A., D'Alfonso, S., Witte, T., Lauwerys, B.R., Endreffy, E., Kovács, L., Vasconcelos, C., Martins, da. Silva. B., Kozyrev, S.V., Alarcón- Riquelme, M.E. 2012. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes and Immunity doi:10.1038/ gene.2011.84.
21. Morgan, A.W., J.I. Robinson, P.G. Conaghan, S.G. Martin, E.M. Hensor, M.D. Morgan, L. Steiner, H.A. Erlich, H.C. Gooi, A. Barton, J. Worthington, and P. Emery. 2010. Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception Cohort. Arthritis Research & Therapy 12: R57.
22. Nakasa, T., H. Shibuya, Y. Nagata, T. Niimoto, and M. Ochi. 2011. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis and Rheumatism 63: 1582-1590.
23. Murata, K., H. Yoshitomi, S. Tanida, M. Ishikawa, K. Nishitani, H. Ito, and T. Nakamura. 2010. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Research & Therapy 12: R86.
24. Nakasa, T., S.Miyaki,A.Okubo,M. Hashimoto,K. Nishida,M.Ochi, and H. Asahara. 2008. Expression of MicroRNA-146 in rheumatoid arthritis synovial tissue. Arthritis and Rheumatism 58: 1284-1292.
25. Franzoso, G., L. Carlson, L. Xing, L. Poljak, E.W. Shores, K.D. Brown, A. Leonardi, T. Tran, B.F. Boyce, and U. Siebenlist. 1997. Requirement for NF-kB in osteoclast and B-cell development. Genes & Development 11: 3482-3496.
26. Clohisy, J.C., B.C. Roy, C. Biondo, E. Frazier, D. Willis, S.L. Teitelbaum, and Y. Abu-Amer. 2003. Direct inhibition of NF-?B blocks bone erosion associated with inflammatory arthritis. Journal of Immunology 171: 5547-5553.
27. Pauley, K.M., M. Satoh, A.L. Chan, M.R. Bubb, W.H. Reeves, and E.K. Chan. 2008. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Research & Therapy 10: R101.
28. Li, J., Y. Wan, Q. Guo, L. Zou, J. Zhang, Y. Fang, J. Zhang, J. Zhang, X. Fu, H. Liu, L. Lu, and Y. Wu. 2010. Research article altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Research & Therapy 12: R81.
29. Ryu, S.W., S.K. Chae, K.J. Lee, and E. Kim. 1999. Identification and characterization of human Fas associated aactor 1, hFAF1. Biochemical and Biophysical Research Communications 262: 388-394.
30. Ryu, S.W., and E. Kim. 2001. Apoptosis Induced by human Fasassociated aactor 1, hFAF1, requires its ubiquitin homologous domain, but not the Fas-binding domain. Biochemical and Biophysical Research Communications 286: 1027-1032.
31. Park, M.Y., H.D. Jang, S.Y. Lee, K.J. Lee, and E. Kim. 2004. Fasassociated factor-1 Inhibits nuclear factor-?B (NF-?B) activity by interfering with nuclear translocation of the RelA (p65) subunit of NF-?B. Journal of Biological Chemistry 279: 1544-1549.
32. Curtale, G., F. Citarella, C. Carissimi, M. Goldoni, N. Carucci, V. Fulci, D. Franceschini, F. Meloni, V. Barnaba, and G. Macino. 2010. An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activationinduced cell death in T lymphocytes. Blood 115: 265-273.
33. Ryu, S.W., S.J. Lee, M.Y. Park, J.I. Jun, Y.K. Jung, and E. Kim. 2003. Fas-Associated factor 1, FAF1, is a member of fas deathinducing signaling complex. Journal of Biological Chemistry 178: 24003-24010.
34. Niimoto, T., T. Nakasa, M. Ishikawa, A. Okuhara, B. Izumi, M. Deie, O. Suzuki, N. Adachi, and M. Ochi. 2010. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskeletal Disorders 11: 209.
35. Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nature Reviews Immunology 7: 454-465.
36. Lu, L.F., T.H. Thai, D.P. Calado, A. Chaudhry, M. Kubo, K. Tanaka, G.B. Loeb, H. Lee, A. Yoshimura, K. Rajewsky, and A.Y. Rudensky. 2009. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells through targeting SOCS1. Immunity 30: 80-91.
37. Chatzikyriakidou, A., P.V. Voulgari, I. Georgiou, and A.A. Drosos. 2010. A polymorphism in the 3'-UTR of interleukin-1 receptorassociated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. Joint, Bone, Spine 77: 411-413.
38. Yang, B., J.L. Zhang, Y.Y. Shi, D.D. Li, J. Chen, Z.C. Huang, B. Cai, X.B. Song, L.X. Li, B.W. Ying, and L.L. Wang. 2011. Association study of single nucleotide polymorphisms in premiRNA and rheumatoid arthritis in a Han Chinese population. Molecular Biology Reports 38: 4913-4919.
39. Pauley, K.M., C.M. Stewart, A.E. Gauna, L.C. Dupre, R. Kuklani, A.L. Chan, B.A. Pauley, W.H. Reeves, E.K. Chan, and S. Cha. 2011. Altered miR-146a expression in Sjögren's syndrome and its functional role in innate immunity. European Journal of Immunology 41: 2029-2039.
40. Bombardieri, M., F. Barone, V. Pittoni, C. Alessandri, P. Conigliaro, M.C. Blades, R. Priori, I.B. McInnes, G. Valesini, and C. Pitzalis. 2004. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Research & Therapy 6: R447-R456.
41. Eriksson, P., C. Andersson, C. Ekerfelt, J. Ernerudh, and T. Skogh. 2004. Relationship between serum levels of IL-18 and IgG1 in patients with primary Sjögren's syndrome, rheumatoid arthritis and healthy controls. Clinical and Experimental Immunology 137: 617-620.
42. Szodoray, P., P. Alex, J.G. Brun, M. Centola, and R. Jonsson. 2004. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scandinavian Journal of Immunology 59: 592-599.
43. Yamano, S., J.C. Atkinson, B.J. Baum, and P.C. Fox. 1999. Salivary gland cytokine expression in NOD and normal BALB/c Mice. Clinical Immunology 92: 265-275.
44. Zilahi, E., T. Tarr, G. Papp, Z. Griger, S. Sipka, and M. Zeher. 2011. Increased microRNA-146a/b, TRAF6 gene and decreased IRAK1 gene expressions in the peripheral mononuclear cells of patients with Sjögren's syndrome. Immunology Letters. doi:10.1016/j.imlet.2011.09.006.